Fundamentals · TMO
Valuation Summary for TMO
AI-generated plain-English read of valuation summary for TMO. Updated daily.
Fair multiples, stable
moderateMultiples (26.7x) sit in fair territory — the market is pricing in roughly what the business can deliver. No valuation edge or urgency; other signals drive the thesis here.
What will probably happen
- Multiples are stable — no near-term catalyst for a valuation re-rating from the multiple direction alone.
What to do
- If you HOLD this stock
- Reasonably priced with stable multiples — a hold-the-line setup. No urgent action from the valuation dimension.
- If you're EVALUATING this stock
- Acceptable entry — fair multiples don't demand a discount premium. Expect returns roughly in line with sector beta.
- If you trade OPTIONS
- No valuation edge from multiples alone. Trade other signals (momentum, earnings) rather than valuation-driven structures.
9 quarters / 3 populated multiples — directionally informative; use more data for full conviction.
Technical details
Technical analysis
- P/Book
- 3.5x
- P/Sales
- 4.1x
- EV/EBITDA
- —
- FCF yield
- —
- EV/Revenue
- —
- P/E (forward)
- —
- Dividend yield
- 0.4%
- Earnings yield
- —
- Income profile
- Growth Profile
- P/E (trailing)
- 26.7x
- Sector context
- Life Sciences Tools & Services
- Sector comparison
- Unknown Vs Sector
- Absolute valuation
- Fairly Valued
- History (quarters)
- 9
- Multiple trajectory
- Stable
Key levels
| Level | Value |
|---|---|
| pb ratio | 3.53 |
| pe ratio | 26.707 |
| ps ratio | 4.056 |
| n quarters | 9 |
| prior year pe | 28.938 |
| dividend yield | 0.004 |
Caveats
- Multiples should be read alongside growth and quality metrics — a low P/E on declining earnings isn't cheap, it's a value trap warning.
- Sector context wasn't provided — absolute multiples may mislead without industry comparison.